Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical… | Phase 1 | terminated | May 20, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | Phase 1 | withdrawn | Apr 6, 2021 | Stanford University | Business Decision | Sponsor / business decision |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03492164 | In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer | Early Phase 1 | terminated | Apr 10, 2018 | Abramson Cancer Center at Penn Medicine | Early analysis of images after 6 patients showed no activity of the radiotracer in this patient… | Other (stated, no rule matched) |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | terminated | May 2, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | N/A | terminated | Apr 13, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Technical difficulties that were not able to be resolved. | Other (stated, no rule matched) |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Sep 15, 2016 | University of Texas Southwestern Medical Center | The study was terminated due to futility and lack of future funding | Efficacy / futility |
| NCT05116917 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.(INFLUENCE) | Phase 2 | terminated | Nov 11, 2021 | Herlev Hospital | Based on the precpecified interim analysis the predictive probability was below 10% for the… | Efficacy / futility |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04698915 | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | Phase 2 | terminated | Jan 7, 2021 | Galera Therapeutics, Inc. | Futility Analysis | Efficacy / futility |
| NCT04090463 | IORT on Borderline Resectable Pancreatic Cancer(PancFORT) | Phase 2 | suspended | Sep 16, 2019 | Universita di Verona | Logistic and financial reasons | Funding |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a… | Phase 2 | terminated | May 15, 2020 | Academic and Community Cancer Research United | Slow accrual | Enrollment / accrual |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid…(MYCure) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Peptomyc S.L. | Phase 1completed; sponsor decided to change strategy to a combination study | Sponsor / business decision |
| NCT03848182 | Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer | Phase 2 | terminated | Feb 20, 2019 | Albert Einstein College of Medicine | Slow accrual | Enrollment / accrual |
| NCT06371716 | Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions | N/A | terminated | Apr 17, 2024 | IRCCS San Raffaele | resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be… | Enrollment / accrual |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | — | terminated | Apr 2, 2024 | Paolo Giorgio Arcidiacono, MD | no patients with inclusion criteria | Other (stated, no rule matched) |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer… | Phase 3 | terminated | Mar 9, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT03724435 | Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry(ARRAY) | — | terminated | Oct 30, 2018 | Focused Ultrasound Foundation | Competing trial will publish similar results | Other (stated, no rule matched) |
| NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment… | Early Phase 1 | terminated | May 8, 2018 | Abramson Cancer Center at Penn Medicine | The accrual goal could not be met and the drug manufacturer pulled support | Drug supply |
| NCT04276909 | Feasibility Study of LUM Imaging System for Pancreatic Cancer | N/A | withdrawn | Feb 19, 2020 | Lumicell, Inc. | Study not initiated. | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT00322712 | INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM… | — | terminated | May 8, 2006 | University of New Mexico | This is only a chart review. This is not a clinical trial and was inadvertently entered in the… | Other (stated, no rule matched) |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage… | N/A | withdrawn | Aug 1, 2013 | All India Institute of Medical Sciences | Lack of interest | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT02722616 | Ultrasound Monitoring of Abdominal Soft Tissue | N/A | terminated | Mar 30, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Ultrasound vendor cannot support the study | Other (stated, no rule matched) |
| NCT03397342 | MRI Only Radiation Therapy With CPAP | N/A | terminated | Jan 12, 2018 | Albert Einstein College of Medicine | Study terminated prematurely well short of enrollment target. Only 5 health participants were… | Enrollment / accrual |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT04592861 | Carbon Ion RT for Locally Advanced Pancreatic Cancer | Phase 3 | terminated | Oct 19, 2020 | Albert Einstein College of Medicine | Study administratively closed out by the Einstein IRB. NO US enrolling sites. | Enrollment / accrual |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects… | Phase 1 | terminated | Jan 18, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated due to the adjustment of sponsor's development strategies and pipeline. | Sponsor / business decision |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | N/A | withdrawn | Jan 27, 2023 | Qure Healthcare, LLC | The study sponsor did not wish to proceed with the study | Other (stated, no rule matched) |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Aug 28, 2018 | University of Texas Southwestern Medical Center | Funding was terminated early because research interests were going in a different direction. | Funding |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic… | Phase 2 | terminated | Feb 28, 2008 | MacroGenics | Corporate decision | Other (stated, no rule matched) |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT06017323 | Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic…(ProglumidePanc) | Phase 1 | withdrawn | Aug 30, 2023 | Georgetown University | STUDY00006987 | Other (stated, no rule matched) |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 19, 2024source: clinicaltrials